Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2022-08-30

FDA Approved: SYNTHROID — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Synthroid (levothyroxine sodium) submitted by AbbVie, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SYNTHROID (LEVOTHYROXINE SODIUM)

Snippet

SUPPL AP for SYNTHROID (LEVOTHYROXINE SODIUM)